We believe that the molecular diagnosis of FHH through DNA sequencing or DHPLC of the CaSR gene is clinically useful in the differential diagnosis of hypercalcemia in elderly patients with multiple comorbidities. This evidence concerns the gene CASR and hypercalcemia disease.